Alzamend Neuro Quote - ALZN

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1.15

Bid

1.14

Offer

1.15

Volume

726,311

1.13 Day's Range 1.22

1.06 52 Week Range 15.06

Market Cap

6.248M

Previous Close

1.25

Open

1.21

Last Trade

300

1.15

Last Trade Time

07:56:01

Financial Volume

US$ 856,374

VWAP

1.1791

Average Volume (3m)

199,413

Shares Outstanding

5,432,797

Dividend Yield

PE Ratio

-0.63

Earnings Per Share (EPS)

-1.83

Revenue

Net Profit

-9.95M

Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipe... Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.alzamend.com

Headquarters

Wilmington, Delaware, USA

Founded

Alzamend Neuro Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALZN. The last closing price for Alzamend Neuro was US$1.25. Over the last year, Alzamend Neuro shares have traded in a share price range of US$ 1.06 to US$ 15.06.

Alzamend Neuro currently has 5,432,797 shares in issue. The market capitalisation of Alzamend Neuro is US$6.79 million. Alzamend Neuro has a price to earnings ratio (PE ratio) of -0.63.

Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo

Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer’s...

Form 8-K - Current report

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice

Alzamend is developing AL001, a lithium product designed for enhanced safety and efficacy compared to currently available FDA-approved and marketed lithium therapies At a low dose, AL001...

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety review committee Identified dose is unlikely to require...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.03	-2.54237288136	1.18	1.34	1.1295	158333	1.23789884	CS
4	-0.15	-11.5384615385	1.3	1.36	1.06	138431	1.24159573	CS
12	-0.55	-32.3529411765	1.7	1.9	1.06	199413	1.52446203	CS
26	-3.039	-72.5471472905	4.189	15.06	1.06	923066	4.87468069	CS
52	-8.85	-88.5	10	15.06	1.06	502792	5.07758129	CS
156	-342.35	-99.6652110626	343.5	366	1.06	540744	127.56912632	CS
260	-4348.85	-99.9735632184	4350	5032.5	1.06	1128961	369.35803457	CS

ALZN - Frequently Asked Questions (FAQ)

What is the current Alzamend Neuro share price?

The current share price of Alzamend Neuro is US$ 1.15

How many Alzamend Neuro shares are in issue?

Alzamend Neuro has 5,432,797 shares in issue

What is the market cap of Alzamend Neuro?

The market capitalisation of Alzamend Neuro is USD 6.79M

What is the 1 year trading range for Alzamend Neuro share price?

Alzamend Neuro has traded in the range of US$ 1.06 to US$ 15.06 during the past year

What is the PE ratio of Alzamend Neuro?

The price to earnings ratio of Alzamend Neuro is -0.63

What is the reporting currency for Alzamend Neuro?

Alzamend Neuro reports financial results in USD

What is the latest annual profit for Alzamend Neuro?

The latest annual profit of Alzamend Neuro is USD -9.95M

What is the registered address of Alzamend Neuro?

The registered address for Alzamend Neuro is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Alzamend Neuro website address?

The website address for Alzamend Neuro is www.alzamend.com

Which industry sector does Alzamend Neuro operate in?

Alzamend Neuro operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AALAmerican Airlines Group Inc	US$ 0.00 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.00 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 0.00 (0.00%)	0
AADIAadi Bioscience Inc	US$ 0.00 (0.00%)	0
AACGATA Creativity Global	US$ 0.00 (0.00%)	0
AALAmerican Airlines Group Inc	US$ 0.00 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.00 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 0.00 (0.00%)	0
AADIAadi Bioscience Inc	US$ 0.00 (0.00%)	0
AACGATA Creativity Global	US$ 0.00 (0.00%)	0
AALAmerican Airlines Group Inc	US$ 0.00 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.00 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 0.00 (0.00%)	0
AADIAadi Bioscience Inc	US$ 0.00 (0.00%)	0
AACGATA Creativity Global	US$ 0.00 (0.00%)	0